01—Abstract
Summary
Summary of the 8-K filed February 24, 2025. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated (Nasdaq: INSM) disclosed on February 24, 2025 that the U.S. Food and Drug Administration does not currently plan to hold an advisory committee meeting to discuss the company's New Drug Application for brensocatib in patients with non-cystic fibrosis bronchiectasis.
The company reported that the FDA communicated this in its Day 74 letter to Insmed. The FDA had previously granted Priority Review to the application and set a Prescription Drug User Fee Act target action date of August 12, 2025. The filing states that the company is committed to working closely with the agency to complete the review.
The company describes brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, as having the potential to become the first and only approved treatment for bronchiectasis and the first in a new class of DPP1 inhibitors. The application is based on data from the ASPEN study, which the company describes as the largest Phase 3 study ever conducted in patients with bronchiectasis.
The disclosure was made under Items 8.01 and 7.01 of Form 8-K, with the press release furnished as Exhibit 99.1. The filing states that brensocatib has not been approved for any indication in any jurisdiction.
02—Key points
Key Highlights
- The FDA does not currently plan to hold an advisory committee meeting to discuss the NDA for brensocatib in non-cystic fibrosis bronchiectasis, per the FDA's Day 74 communication.
- The NDA holds Priority Review, with a PDUFA target action date of August 12, 2025.
- The application is based on data from the ASPEN study, described by the company as the largest Phase 3 study ever conducted in patients with bronchiectasis.
- Brensocatib is described as a potential first and only approved treatment for bronchiectasis and the first DPP1 inhibitor for neutrophil-mediated diseases.
- The company cites approximately 500,000 diagnosed bronchiectasis patients in the U.S., 600,000 in the EU5, and 150,000 in Japan, with no approved therapies specifically targeting the condition in these regions.
- Brensocatib remains investigational and has not been approved for any indication in any jurisdiction.
- The press release is furnished under Item 7.01 and is not deemed filed for purposes of Section 18 of the Exchange Act.
03—Questions
Frequently Asked Questions
Will the FDA convene an advisory committee to review brensocatib?
Not currently. Insmed announced that the FDA does not currently plan to hold an advisory committee meeting to discuss the NDA for brensocatib in non-cystic fibrosis bronchiectasis, as communicated in the FDA's Day 74 letter.
When is the FDA's target action date for brensocatib?
The FDA set a PDUFA target action date of August 12, 2025, under Priority Review, and the company reaffirmed this date in the press release.
What data supports the brensocatib application?
The NDA is based on data from the ASPEN study, which the company describes as the largest Phase 3 study ever conducted in patients with bronchiectasis.
Has brensocatib been approved anywhere?
No. The filing states that brensocatib is an investigational drug product that has not been approved for any indication in any jurisdiction.
What is the size of the bronchiectasis patient population?
The company cites approximately 500,000 diagnosed patients in the U.S., 600,000 in the EU5 (France, Germany, Italy, Spain, and UK), and 150,000 in Japan.
04—Continue